[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 42 of about 42
1. Neville HL, Raney RB, Andrassy RJ, Cooley DA: Multidisciplinary management of pediatric soft-tissue sarcoma. Oncology (Williston Park); 2000 Oct;14(10):1471-81; discussion 1482-6, 1489-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidisciplinary management of pediatric soft-tissue sarcoma.
  • The management of pediatric soft-tissue sarcomas has improved drastically through the use of multimodal therapy.
  • However, approaches to therapy for the two tumor types remain somewhat different.
  • Rhabdomyosarcomas are treated primarily with chemotherapy.
  • Radiation therapy is reserved for patients with persistent or recurrent disease and may be delivered by external beam or brachytherapy.
  • Nonrhabdomyosarcomas are best treated primarily by surgical resection, although radiation and chemotherapy are now being used with some success.
  • Multimodal therapy has led to improved survival as well as better functional and cosmetic results.
  • With further clinical trials and improved techniques such as brachytherapy and lymphatic mapping with sentinel node biopsy, we expect to continue to optimize therapy for pediatric patients with soft-tissue sarcomas.
  • [MeSH-major] Rhabdomyosarcoma / therapy. Sarcoma / therapy. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Child. Combined Modality Therapy. Humans. Neoplasm Staging

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11098512.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 25
  •  go-up   go-down


2. Sleijfer S, van der Graaf WT, Blay JY: Angiogenesis inhibition in non-GIST soft tissue sarcomas. Oncologist; 2008 Nov;13(11):1193-200
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiogenesis inhibition in non-GIST soft tissue sarcomas.
  • Because angiogenesis is of crucial importance in the pathogenesis of cancer, blocking the function of proangiogenic factors has been shown to improve the outcomes of patients with several cancer types.
  • Given the poor survival durations of patients with advanced soft-tissue sarcomas (STSs), which has remained stable at a median of 12 months over the last 20 year, there is an unmet need for novel agents active against these tumors.
  • Like in other tumors, accumulating evidence points at an important role for angiogenic factors in STSs, rendering these factors attractive treatment targets.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Neovascularization, Pathologic / drug therapy. Sarcoma / drug therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Resistance, Neoplasm. Humans. Protein Kinase Inhibitors / therapeutic use. Receptors, Vascular Endothelial Growth Factor / physiology. Vascular Endothelial Growth Factor A / analysis. Vascular Endothelial Growth Factor A / physiology

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18987047.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Protein Kinase Inhibitors; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  • [Number-of-references] 41
  •  go-up   go-down


3. Bisogno G, Sotti G, Nowicki Y, Ferrari A, Garaventa A, Zanetti I, Favre C, Schiavetti A, Tamaro P, Carli M: Soft tissue sarcoma as a second malignant neoplasm in the pediatric age group. Cancer; 2004 Apr 15;100(8):1758-65
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft tissue sarcoma as a second malignant neoplasm in the pediatric age group.
  • BACKGROUND: Survivors of childhood malignancies have an increased risk of developing second malignant neoplasms (SMN) due to their prior treatment and/or genetic susceptibility.
  • A small proportion of SMNs are soft tissue sarcomas (STS), whose prognosis is generally thought to be poor, though publications on such patients' treatment and outcome is limited.
  • The primary tumor was STS in five patients; Hodgkin disease in five patients; leukemia in four patients; retinoblastoma, neuroblastoma, and Wilms tumor in two patients each; and other tumor types in five patients.
  • SMNs occurred after a median of 8 years (range, 1.9-15.0 years) and included rhabdomyosarcoma (RMS) in 4 patients, malignant peripheral nerve sheath tumor in 4 patients, extraosseous Ewing family tumor (EFT) in 4 patients, leiomyosarcoma in 3 patients, fibrosarcoma in 2 patients, synovial sarcoma in 2 patients, and other tumor types in 6 patients.
  • Treatment generally was administered according to the guidelines for primary STS.
  • RESULTS: Seven non-RMS patients with STS underwent surgery alone, whereas 18 patients received chemotherapy and 8 patients received radiotherapy.
  • Fifteen patients were alive in complete remission of their SMN at the time of last follow-up.
  • Responses to chemotherapy and survival were satisfactory for patients with tumors such as RMS and EFT.
  • Complete tumor resection was correlated with a favorable prognosis in patients with other types of STS and in patients with postirradiation sarcoma.
  • Two patients developed a third malignancy.
  • CONCLUSIONS: Although prior treatment may hinder the management of these patients, pediatric STS second malignancies can be cured using the same strategies used for de novo pediatric sarcomas.
  • Long-term follow-up is mandatory given the risks of further malignancies and more severe, treatment-related side effects.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms, Second Primary. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Prognosis. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 American Cancer Society.
  • (PMID = 15073867.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Oda Y, Saito T, Tateishi N, Ohishi Y, Tamiya S, Yamamoto H, Yokoyama R, Uchiumi T, Iwamoto Y, Kuwano M, Tsuneyoshi M: ATP-binding cassette superfamily transporter gene expression in human soft tissue sarcomas. Int J Cancer; 2005 May 10;114(6):854-62
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ATP-binding cassette superfamily transporter gene expression in human soft tissue sarcomas.
  • However, their expression levels and distribution within soft tissue sarcomas remain controversial.
  • In 86 cases of surgically resected soft tissue sarcoma, intrinsic mRNA levels of MDR1, MRP1, MRP2 and MRP3 were assessed using a quantitative reverse transcriptase-PCR (RT-PCR) method.
  • Among the various histologic types, malignant peripheral nerve sheath tumor (MPNST) showed significantly high levels of MDR1 (p=0.017) and MRP3 (p=0.0384) mRNA expression, compared to the other tumor types.
  • Our results suggest that MDR1/P-gp expression may have an important role to play in tumor progression in the cases of soft tissue sarcoma, and p53 may be one of the active regulators of the MDR1 transcript.
  • In addition, the high levels of both MDR1 and MRP3 mRNA expression in MPNST may help to explain the poor response of this tumor to anticancer-drugs.
  • [MeSH-major] ATP-Binding Cassette Transporters / biosynthesis. ATP-Binding Cassette Transporters / genetics. Drug Resistance, Multiple. Gene Expression Regulation, Neoplastic. Genes, p53. Sarcoma / drug therapy. Sarcoma / genetics
  • [MeSH-minor] Adolescent. Adult. Disease Progression. Drug Resistance, Neoplasm / genetics. Female. Gene Expression Profiling. Humans. Immunohistochemistry. Male. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15609299.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ATP-Binding Cassette Transporters
  •  go-up   go-down


5. Stoeckle E, Gardet H, Coindre JM, Kantor G, Bonichon F, Milbéo Y, Thomas L, Avril A, Bui BN: Prospective evaluation of quality of surgery in soft tissue sarcoma. Eur J Surg Oncol; 2006 Dec;32(10):1242-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective evaluation of quality of surgery in soft tissue sarcoma.
  • BACKGROUND: Prospective application of the French Sarcoma Group (FSG) method of surgery reporting in soft tissue sarcoma (STS) in a single centre.
  • Resection types according to FSG were R0 in 147, R1 in 53 and R2 in five cases.
  • Radiotherapy was delivered in 163 patients and chemotherapy in 103.
  • At univariate analysis, significant prognosticators for LR were age, histotype, tumour invasion, grade and resection type R.
  • [MeSH-major] Extremities. Neoplasm Recurrence, Local. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm, Residual. Prognosis. Risk Factors

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16793237.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


6. Gadducci A, Romanini A: Adjuvant chemotherapy in early stage uterine sarcomas: an open question. Eur J Gynaecol Oncol; 2001;22(5):352-7
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemotherapy in early stage uterine sarcomas: an open question.
  • The most common histological types are represented by leiomyosarcoma, endometrial stromal sarcoma, and carcinosarcoma.
  • The mainstay of treatment of stage I-II disease is total hysterectomy with bilateral salpingo-oophorectomy.
  • Adjuvant chemotherapy is a logical approach, since distant recurrences are more frequent than local failures.
  • The chemotherapy regimens commonly used in advanced uterine sarcomas are similar to the ones for advanced soft tissue sarcomas, with anthracyclines and ifosfamide as the most active drugs.
  • It is advisable to design international cooperative randomized trials with the aim of defining the role of adjuvant chemotherapy in the treatment of early stage uterine sarcomas.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Sarcoma / drug therapy. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Female. Humans. Neoplasm Staging. Radiotherapy, Adjuvant. Randomized Controlled Trials as Topic

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11766739.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 100
  •  go-up   go-down


7. Zawitkowska-Klaczyńska J, Katski K, Woźniak M, Kowalczyk JR: Characteristics and outcome of children with primary soft tissue sarcomas of extremities. Med Wieku Rozwoj; 2004 Apr-Jun;8(2 Pt 1):169-74
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics and outcome of children with primary soft tissue sarcomas of extremities.
  • OBJECTIVES: To determine the characteristics and outcome or patients with primary soft tissue sarcomas of extremities in children.
  • MATERIAL AND METHODS: Thirty-six patients treated for soft tissues sarcomas were enrolled into the study.
  • Features analysed: the incidence of soft tissues sarcoma of extremities, the time from first clinical symptoms to making the diagnosis, the primary site of tumour; histopathologic type of tumour, stage of disease, methods and results of the treatment.
  • RESULTS: The time From first symptoms to making the diagnosis was 5.4 months (mean).
  • Histopathologic types: synovial sarcoma in 4 patients, malignant haemangiopericytoma in 2, rhabdomyosarcoma in 2, sarcoma myogenes in 1, primitive neuroectodermal tumour in l.
  • Patients underwent treatment according to the soft tissue sarcoma protocols.
  • Results of treatment: first complete remission was observed in 7 patients; second complete remission in 1, one patient is on postoperative treatment.
  • Combined treatment achieves full remission in the majority of patients with soft tissues sarcomas localized within the limbs.
  • 2. In patients with large tumours (>5 cm) the treatment should to be started with inductive chemotherapy, and the surgery should be postponed.
  • 3. Early excision of the tumour should be considered in cases of small tumours (< 5 cm), when resection with wide margin of healthy tissues is possible, without deteriorating the function of the limb or cosmetic damage.
  • [MeSH-major] Arm. Leg. Sarcoma / diagnosis. Sarcoma / therapy
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Disease-Free Survival. Female. Hemangiopericytoma / diagnosis. Hemangiopericytoma / therapy. Humans. Incidence. Male. Myosarcoma / diagnosis. Myosarcoma / therapy. Neoplasm Staging. Neuroectodermal Tumors / diagnosis. Neuroectodermal Tumors / therapy. Poland / epidemiology. Retrospective Studies. Rhabdomyosarcoma / diagnosis. Rhabdomyosarcoma / therapy. Sarcoma, Synovial / diagnosis. Sarcoma, Synovial / therapy. Survival Analysis. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15738590.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


8. Leyvraz S, Herrmann R, Guillou L, Honegger HP, Christinat A, Fey MF, Sessa C, Wernli M, Cerny T, Dietrich D, Pestalozzi B, Swiss Group for Clinical Cancer Research (SAKK): Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies. Br J Cancer; 2006 Nov 20;95(10):1342-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies.
  • Having determined in a phase I study the maximum tolerated dose of high-dose ifosfamide combined with high-dose doxorubicin, we now report the long-term results of a phase II trial in advanced soft-tissue sarcomas.
  • Forty-six patients with locally advanced or metastatic soft-tissue sarcomas were included, with age <60 years and all except one in good performance status (0 or 1).
  • The chemotherapy treatment consisted of ifosfamide 10 g m(-2) (continuous infusion for 5 days), doxorubicin 30 mg m(-2) day(-1) x 3 (total dose 90 mg m(-2)), mesna and granulocyte-colony stimulating factor.
  • Twenty-two patients responded to therapy, including three complete responders and 19 partial responders for an overall response rate of 48% (95% CI: 33-63%).
  • The response rate was not different between localised and metastatic diseases or between histological types, but was higher in grade 3 tumours.
  • Salvage therapies (surgery and/or radiotherapy) were performed in 43% of patients and found to be the most significant predictor for favourable survival (exploratory multivariate analysis).
  • Prolonged survival was mainly a function of salvage therapies.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Salvage Therapy. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Male. Middle Aged. Prognosis. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1537-45 [7602342.001]
  • [Cites] Lancet. 1994 Mar 26;343(8900):763-4 [7510815.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):350-62 [8996162.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1418-26 [9193334.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2378-84 [9196153.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1438-43 [9552049.001]
  • [Cites] Am J Clin Oncol. 1998 Jun;21(3):317-21 [9626808.001]
  • [Cites] Ann Oncol. 1998 Aug;9(8):877-84 [9789611.001]
  • [Cites] Ann Oncol. 1998 Aug;9(8):917-9 [9789617.001]
  • [Cites] Cancer. 1999 Jan 15;85(2):389-95 [10023707.001]
  • [Cites] Curr Opin Oncol. 1999 Jul;11(4):285-95 [10416881.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):150-7 [10458228.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):105-12 [15625365.001]
  • [Cites] Curr Opin Oncol. 2005 Jul;17(4):370-5 [15933471.001]
  • [Cites] Ann Oncol. 1999 Sep;10(9):1087-94 [10572607.001]
  • [Cites] Cancer. 1999 Nov 15;86(10):2034-7 [10570428.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(14):2676-84 [10894866.001]
  • [Cites] J Pediatr Hematol Oncol. 2002 Feb;24(2):101-5 [11990694.001]
  • [Cites] J Clin Oncol. 2002 Jun 15;20(12):2824-31 [12065559.001]
  • [Cites] Eur J Cancer. 2002 Dec;38(18):2397-406 [12460784.001]
  • [Cites] Eur J Cancer. 2003 Jan;39(1):64-9 [12504660.001]
  • [Cites] Cochrane Database Syst Rev. 2003;(3):CD003293 [12917960.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):890-9 [14990645.001]
  • [Cites] Cancer. 2004 Apr 1;100(7):1498-506 [15042685.001]
  • [Cites] J Surg Oncol. 2004 Oct 1;88(1):44-9 [15384088.001]
  • [Cites] Ann Oncol. 2004;15 Suppl 4:iv193-6 [15477307.001]
  • [Cites] Cancer. 1973 Jul;32(1):1-8 [4716773.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • [Cites] J Clin Oncol. 1986 Aug;4(8):1277-8 [3734850.001]
  • [Cites] J Clin Oncol. 1987 Jun;5(6):833-5 [3295127.001]
  • [Cites] J Clin Oncol. 1989 Jan;7(1):126-31 [2491883.001]
  • [Cites] J Clin Oncol. 1990 Dec;8(12):1935-7 [2230885.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1269-75 [8315424.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1600-8 [7541449.001]
  • (PMID = 17031396.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  • [Other-IDs] NLM/ PMC2360595
  •  go-up   go-down


9. Lehnhardt M, Daigeler A, Homann HH, Hauser J, Langer S, Steinsträsser L, Soimaru C, Puls A, Steinau HU: [Importance of specialized centers in diagnosis and treatment of extremity-soft tissue sarcomas. Review of 603 cases]. Chirurg; 2009 Apr;80(4):341-7
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Importance of specialized centers in diagnosis and treatment of extremity-soft tissue sarcomas. Review of 603 cases].
  • [Transliterated title] Die Bedeutung von Referenzzentren in Diagnose und Therapie von Weichgewebssarkomen der Extremitäten. Auswertung von 603 Fällen.
  • Correct histopathologic diagnosis is essential for adequate treatment of soft tissue sarcomas.
  • Due to the disorder's rarity, multitude of subgroups, sometimes varying histopathologic appearance, and occasionally inadequate biopsy specimens, diagnosis and grading are challenging.
  • The records of 603 patients with soft tissue tumors of the extremities were reviewed concerning mismatches in primary and definite diagnoses relating to entity, evaluation of primary or recurrent tumor specimens, and the diagnosing pathology institution.
  • In the eight most frequent sarcoma types, malignant peripheral nerve sheath tumors and leiomyosarcoma had the highest rates of false primary diagnosis, 78.4% and 74.2% of cases, respectively.
  • For optimal treatment of soft tissue sarcomas, we suggest obtaining expert second opinion to ensure adequate surgical therapy and precise indications for radiation and chemotherapy.
  • [MeSH-major] Cancer Care Facilities. Extremities / surgery. Hospitals, Special. Hospitals, University. Sarcoma / diagnosis. Sarcoma / surgery. Soft Tissue Neoplasms / diagnosis. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Child. Combined Modality Therapy. Diagnostic Errors. Female. Germany. Histiocytoma, Benign Fibrous / diagnosis. Histiocytoma, Benign Fibrous / pathology. Histiocytoma, Benign Fibrous / surgery. Humans. Leiomyosarcoma / diagnosis. Leiomyosarcoma / pathology. Leiomyosarcoma / surgery. Liposarcoma / diagnosis. Liposarcoma / pathology. Liposarcoma / surgery. Male. Middle Aged. Neoplasm Staging. Nerve Sheath Neoplasms / diagnosis. Nerve Sheath Neoplasms / pathology. Nerve Sheath Neoplasms / surgery. Radiotherapy, Adjuvant. Referral and Consultation. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 2001 Oct;116(4):473-6 [11601130.001]
  • [Cites] Cancer Treat Res. 2004;120:43-63 [15217217.001]
  • [Cites] Invest New Drugs. 2006 May;24(3):249-53 [16133789.001]
  • [Cites] Int J Hyperthermia. 2006 May;22(3):235-9 [16754344.001]
  • [Cites] Arch Pathol Lab Med. 1995 Jun;119(6):514-7 [7605166.001]
  • [Cites] Curr Oncol Rep. 2005 Jul;7(4):300-6 [15946590.001]
  • [Cites] Can J Surg. 1988 Nov;31(6):404-6 [3179848.001]
  • [Cites] Am J Surg Pathol. 1992 Mar;16(3):213-28 [1317996.001]
  • [Cites] Chirurg. 2001 May;72(5):501-13 [11383061.001]
  • [Cites] J Surg Oncol. 2008 Jan 1;97(1):40-3 [17918224.001]
  • [Cites] Chirurg. 2004 Dec;75(12):1182-90 [15309264.001]
  • [Cites] Ann Diagn Pathol. 1999 Feb;3(1):48-61 [9990113.001]
  • [Cites] Curr Top Pathol. 1995;89:123-51 [7882706.001]
  • [Cites] Eur J Cancer. 2002 Mar;38(4):556-9 [11872349.001]
  • [Cites] Curr Treat Options Oncol. 2004 Dec;5(6):451-62 [15509479.001]
  • [Cites] Pathol Res Pract. 1988 Nov;183(6):698-705 [2851775.001]
  • [Cites] Histopathology. 2006 Jan;48(1):3-12 [16359532.001]
  • [Cites] Invest New Drugs. 2003 Nov;21(4):481-6 [14586217.001]
  • [Cites] Acta Orthop Scand Suppl. 2004 Apr;75(311):77-86 [15188669.001]
  • [Cites] Cancer. 1999 Dec 1;86(11):2426-35 [10590387.001]
  • [Cites] Clin Orthop Relat Res. 1999 Nov;(368):212-9 [10613171.001]
  • [Cites] Bull Cancer. 2001 Aug;88(8):765-73 [11578945.001]
  • [Cites] Curr Oncol Rep. 2006 Jul;8(4):305-9 [17254531.001]
  • [Cites] Cancer. 1986 Jul 15;58(2):306-9 [3719523.001]
  • [Cites] J Bone Joint Surg Am. 1996 May;78(5):656-63 [8642021.001]
  • [Cites] Hum Pathol. 2002 Jan;33(1):111-5 [11823981.001]
  • [Cites] Chirurg. 2007 Jan;78(1):62-4 [16786340.001]
  • [Cites] Lancet Oncol. 2000 Oct;1:75-85 [11905672.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Feb;41(2):157-67 [11856592.001]
  • [Cites] Expert Rev Anticancer Ther. 2004 Apr;4(2):237-46 [15056054.001]
  • [Cites] Mod Pathol. 2007 Jul;20(7):749-59 [17464315.001]
  • [Cites] Verh Dtsch Ges Pathol. 2006;90:59-72 [17867581.001]
  • [Cites] Cancer Treat Res. 1993;67:1-22 [8102867.001]
  • [Cites] Am J Clin Pathol. 2000 Sep;114(3):329-35 [10989631.001]
  • [Cites] Br J Cancer. 1991 Aug;64(2):315-20 [1892759.001]
  • (PMID = 18523742.001).
  • [ISSN] 1433-0385
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


10. Fang Z, Matsumoto S, Ae K, Kawaguchi N, Yoshikawa H, Ueda T, Ishii T, Araki N, Kito M: Postradiation soft tissue sarcoma: a multiinstitutional analysis of 14 cases in Japan. J Orthop Sci; 2004;9(3):242-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postradiation soft tissue sarcoma: a multiinstitutional analysis of 14 cases in Japan.
  • Radiation therapy (RT) is commonly used to treat malignant tumors, but it leads to side effects and complications.
  • This article focuses on the clinical manifestations, pathological characteristics, and therapeutic effects concerning postradiation soft tissue sarcomas (PRSTSs).
  • Their histological types were malignant fibrous histiocytoma (eight cases), extraskeletal osteosarcoma (four cases), fibrosarcoma (one case), and leiomyosarcoma (one case).
  • The primary diagnoses, RT history, latent period, and outcome of treatment were studied retrospectively.
  • There were 13 women and 1 man, with ages ranging from 23 to 77 years (mean 58 years) at the time of the appearance of the PRSTS.
  • RT doses ranged from 48 to 91 Gy (mean 62 Gy).
  • One of three who underwent RT and one of five who underwent chemotherapy (CT) responded.
  • Because adjuvant therapies including RT and CT had a poor effect on PRSTSs, the primary treatment of PRSTSs should be radical resection with a wide margin.
  • [MeSH-major] Neoplasms, Second Primary / surgery. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Breast Neoplasms / radiotherapy. Female. Histiocytoma, Benign Fibrous / etiology. Histiocytoma, Benign Fibrous / surgery. Humans. Japan. Male. Middle Aged. Neoplasm Recurrence, Local. Radiotherapy / adverse effects. Radiotherapy Dosage. Uterine Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] The Japanese Orthopaedic Association
  • (PMID = 15168177.001).
  • [ISSN] 0949-2658
  • [Journal-full-title] Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association
  • [ISO-abbreviation] J Orthop Sci
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Japan
  •  go-up   go-down


11. Cecchetto G, Guglielmi M, Inserra A, Zanetti I, Dall'Igna P, Gigante C, Carli M, Italian Cooperative Group on Soft-tissue Sarcomas: Primary re-excision: the Italian experience in patients with localized soft-tissue sarcomas. Pediatr Surg Int; 2001 Sep;17(7):532-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary re-excision: the Italian experience in patients with localized soft-tissue sarcomas.
  • Primary re-excision (PRE) is a wide, non-mutilating procedure carried out in patients with soft-tissue sarcomas (STS) when microscopic residuals are left after initial excision or when there are insufficient data on its completeness.
  • Of the 53 patients, 45 had complete histologic excision of the tumor (residuals were found in 21/45 specimens) and subsequently received chemotherapy (CT) alone: 39/45 are in their first complete remission (CR) with a median follow-up of 53 months; 6/45 (3 RMS, 3 NRSTS) relapsed, 4 locally (2 extremities, 2 trunk), and 1 of these died of progressive disease, and 2 with metastatic spread died of their disease.
  • The histologic types and the presence of residuals at PRE did not predict the failures; PRE was effective especially in extremity, trunk, and paratesticular sites, whereas its role was uncertain in large sarcomas over 5 cm in size.
  • [MeSH-major] Rhabdomyosarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Head and Neck Neoplasms / surgery. Humans. Infant. Italy. Male. Neoplasm Staging. Testicular Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11666052.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


12. Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schöffski P, Collin F, Pandite L, Marreaud S, De Brauwer A, van Glabbeke M, Verweij J, Blay JY: Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol; 2009 Jul 1;27(19):3126-32
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).
  • PURPOSE Given the importance of angiogenesis in soft tissue sarcoma (STS), pazopanib, an oral angiogenesis inhibitor that targets vascular endothelial growth factor receptor and platelet-derived growth factor receptor, was explored in patients with advanced STS.
  • PATIENTS AND METHODS Patients with intermediate- or high-grade advanced STS who were ineligible for chemotherapy or who had received no more than two prior cytotoxic agents for advanced disease, who had documented progression, who had adequate performance status, and who had good organ function were eligible.
  • Four different strata were studied: adipocytic STS, leiomyosarcomas, synovial sarcomas, and other STS types.
  • PFR(12 weeks) was 18 (44%) of 41 patients in the leiomyosarcoma cohort, 18 (49%) of 37 in the synovial sarcomas, and 16 (39%) of 41 in the other STS types.
  • Compared with historical controls who were treated with second-line chemotherapy, progression-free and overall survivals were prolonged in the three cohorts in which the primary end point was reached.
  • The most frequent drug-related toxicities were hypertension, fatigue, hypopigmentation, and nausea.
  • CONCLUSION Pazopanib is well tolerated in patients with relapsed, advanced STS and demonstrates interesting activity that warrants additional study in patients with leiomyosarcomas, synovial sarcomas, and other STS types.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Pyrimidines / therapeutic use. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy. Sulfonamides / therapeutic use
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / mortality

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • Genetic Alliance. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19451427.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Pyrimidines; 0 / Sulfonamides; 7RN5DR86CK / pazopanib
  •  go-up   go-down


13. Kazanowska B, Mikołajewska A, Balcerska A, Balwierz W, Bodalski J, Dłuzniewska A, Drozyńska E, Kurylak A, Reich A, Stencel D, Szewczyk B, Wachowiak J, Wysocki M, Chybicka A: [Soft tissue sarcoma of the bladder and prostate. A report of the Polish Paediatric Solid Tumour Group (PPSTG)]. Med Wieku Rozwoj; 2004 Oct-Dec;8(4 Pt 2):1091-8
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Soft tissue sarcoma of the bladder and prostate. A report of the Polish Paediatric Solid Tumour Group (PPSTG)].
  • Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children younger then 15 years of age.
  • The treatment of RMS localized in bladder or prostate still remains controversial.
  • The aim of this study was analysis of treatment results in children with soft tissue sarcoma of bladder and prostate.
  • From 1993 to 2001 the PPSTG has used three protocols to treat soft tissue sarcomas in children.
  • After biopsy confirmation of the diagnosis patients were treated with chemotherapy and subsequent surgery.
  • The median follow-up time was 42 months.
  • RMS-embryonal was diagnosed in 11 patients, RMS-alveolare in 4 and others types in 4.
  • After induction chemotherapy two patients received partial cystectomy, 5 complete cystectomy and 3 complete cystectomy with genitourinary reconstructive.
  • The most common treatment failure was isolated, local relapse in 8 children particularly in patients with any second surgery.
  • Significant prognostic factors are the initial tumours volume, the lymph nodes infiltration and the response to the first chemotherapy cycle.
  • Surgery is the most important procedure in local control of soft tissue sarcoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Prostatic Neoplasms. Rhabdomyosarcoma. Urinary Bladder Neoplasms
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Child, Preschool. Cystectomy / methods. Female. Follow-Up Studies. Humans. Infant. Male. Neoplasm Staging. Poland. Radiotherapy, Adjuvant. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15951604.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


14. Komdeur R, Plaat BE, van der Graaf WT, Hoekstra HJ, Hollema H, van den Berg E, Zwart N, Scheper RJ, Molenaar WM: Expression of multidrug resistance proteins, P-gp, MRP1 and LRP, in soft tissue sarcomas analysed according to their histological type and grade. Eur J Cancer; 2003 May;39(7):909-16
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of multidrug resistance proteins, P-gp, MRP1 and LRP, in soft tissue sarcomas analysed according to their histological type and grade.
  • The biological behaviour of different histological types and grades of soft tissue sarcomas (STS) varies.
  • This might result in a differing sensitivity to cytotoxic drugs.
  • Cross-resistance to functionally and structurally distinct natural-product drugs, known as multidrug resistance (MDR), is associated with the overexpression of P-glycoprotein (P-gp), multidrug resistance-associated protein 1 (MRP1) and lung resistance-related protein (LRP).
  • The purpose of this study was to evaluate the expression of P-gp, MRP1 and LRP in STS according to their histological type and grade.
  • In 141 chemotherapy-naive STS patients, the expression of the three MDR proteins was detected by immunohistochemistry.
  • Nine histological types were documented.
  • In conclusion, P-gp, MRP1 and LRP are expressed in the majority of STS, but this expression varies according to the histological type.
  • [MeSH-major] Multidrug Resistance-Associated Proteins / metabolism. Neoplasm Proteins / metabolism. P-Glycoproteins / metabolism. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy. Vault Ribonucleoprotein Particles / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Drug Resistance, Multiple. Drug Resistance, Neoplasm. Female. Humans. Immunohistochemistry / methods. Infant. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12706359.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ABCC4 protein, human; 0 / Multidrug Resistance-Associated Proteins; 0 / Neoplasm Proteins; 0 / P-Glycoproteins; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein
  •  go-up   go-down


15. Matsumoto S, Kawaguchi N, Manabe J, Tanizawa T, Koyama S, Ae K, Shimoji T: [Surgical treatment for bone and soft tissue sarcoma]. Gan To Kagaku Ryoho; 2004 Sep;31(9):1314-8
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment for bone and soft tissue sarcoma].
  • There are many kinds of wide excision or wide resection, which are methods to remove the tumor with surrounding tissues.
  • The curability of wide resection depends on the range and characteristics of the normal surrounding tissues.
  • The so-called "Safety surgical margin" is the margin that prevents local recurrence due to insufficient surgical treatment.
  • Local recurrence due to other causes can not be treated by surgery alone as chemotherapy is also required.
  • For example, the infiltrative type of malignant fibrous histiocytoma requires a curative procedure.
  • On the other hand, non-infiltrative types of sarcoma or high-grade sarcoma, which are good responders to preoperative treatment, are locally controlled by an adequate wide margin procedure.
  • Once postoperative complications occur, patients must remain in the hospital for a long time.
  • To prevent this, the preservation of normal tissue, meaning reduction of surgical margin, is important.
  • [MeSH-major] Bone Neoplasms / surgery. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Blood Vessel Prosthesis Implantation. Humans. Lymphatic Metastasis. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / prevention & control. Quality of Life. Surgical Procedures, Operative / methods. Survival Rate

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15446549.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 6
  •  go-up   go-down


16. Do L, Puthawala A, Syed N, Azawi S, Williams R, Vora N: Treatment outcomes of T4 locally advanced head and neck cancers with soft tissue invasion or bone and cartilage invasion. Am J Clin Oncol; 2009 Oct;32(5):477-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment outcomes of T4 locally advanced head and neck cancers with soft tissue invasion or bone and cartilage invasion.
  • Because the organ preservation trials, more patients with BCI, as well as those with soft tissue invasion (STI), have been treated with definitive CRT.
  • MATERIALS/METHODS: We performed a retrospective review of patients who underwent definitive CRT or radical resection followed up with postoperative CRT for T4N0-3M0 locally advanced SCCHN.
  • We analyzed outcomes based on STI/BCI and types of treatment.
  • Radiotherapy doses ranged from 59.4 to 72 Gy.
  • Concurrent chemotherapy was platinum based in all CRT patients.
  • [MeSH-major] Bone Neoplasms / secondary. Carcinoma, Squamous Cell / therapy. Head and Neck Neoplasms / therapy. Soft Tissue Neoplasms / secondary
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Cartilage / pathology. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19506456.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


17. Fiegl M, Schlemmer M, Wendtner CM, Abdel-Rahman S, Fahn W, Issels RD: Ifosfamide, carboplatin and etoposide (ICE) as second-line regimen alone and in combination with regional hyperthermia is active in chemo-pre-treated advanced soft tissue sarcoma of adults. Int J Hyperthermia; 2004 Sep;20(6):661-70
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ifosfamide, carboplatin and etoposide (ICE) as second-line regimen alone and in combination with regional hyperthermia is active in chemo-pre-treated advanced soft tissue sarcoma of adults.
  • PURPOSE: To evaluate the efficacy and safety of the combination of ICE (ifosfamide 1.5 g m(-2), carboplatin 100 mg m(-2) and etoposide 150 mg m(-2), days 1-4, q 28 days, G-CSF 5 microg kg(-1) starting from day 6) alone and in combination with regional hyperthermia (RHT) in soft tissue sarcoma (STS) refractory to previous standard doxorubicin-ifosfamide-based chemotherapy.
  • PATIENTS AND METHODS: Twenty patients with advanced STS of different histological sub-types were treated with the ICE regimen with 13 patients receiving additional RHT.
  • After a median follow-up time of 15 months, median time to progression was 6 months.
  • CONCLUSION: These results suggest that ICE alone or combined with RHT shows activity as second-line therapy in doxorubicin-ifosfamide-refractory STS.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / therapeutic use. Etoposide / therapeutic use. Hyperthermia, Induced / methods. Ifosfamide / therapeutic use. Sarcoma / therapy
  • [MeSH-minor] Adolescent. Adult. Combined Modality Therapy / adverse effects. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Drug Resistance, Neoplasm. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Granulocyte Colony-Stimulating Factor / adverse effects. Humans. Leukopenia / etiology. Male. Middle Aged. Neoplasm Staging. Patient Selection. Salvage Therapy / methods. Survival Rate. Thrombocytopenia / etiology. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15370821.001).
  • [ISSN] 0265-6736
  • [Journal-full-title] International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  • [ISO-abbreviation] Int J Hyperthermia
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; BG3F62OND5 / Carboplatin; UM20QQM95Y / Ifosfamide; ICE protocol 3
  •  go-up   go-down


18. Mocellin S, Provenzano M, Lise M, Nitti D, Rossi CR: Increased TIA-1 gene expression in the tumor microenvironment after locoregional administration of tumor necrosis factor-alpha to patients with soft tissue limb sarcoma. Int J Cancer; 2003 Nov 1;107(2):317-22
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased TIA-1 gene expression in the tumor microenvironment after locoregional administration of tumor necrosis factor-alpha to patients with soft tissue limb sarcoma.
  • Although it is known that TNF-alpha is effective in the treatment of advanced solid tumors such as melanoma and soft tissue sarcoma, the molecular mechanism underlying its anticancer activity remains unclear.
  • Nineteen patients with locally advanced soft tissue sarcoma underwent isolated limb perfusion with doxorubicin alone (n = 9) or combined with TNF-alpha (n = 10).
  • On the basis of in vivo findings, we investigated the in vitro gene expression of different cell types representing the tumor microenvironment cell population.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Membrane Proteins / genetics. Proteins. RNA-Binding Proteins / genetics. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy. Tumor Necrosis Factor-alpha / therapeutic use
  • [MeSH-minor] Antigens, CD / genetics. Antigens, CD / metabolism. Biopsy. Chemotherapy, Cancer, Regional Perfusion / methods. DNA Primers / chemistry. Doxorubicin / administration & dosage. Endothelium, Vascular / metabolism. Fibroblasts / metabolism. Granulocyte Colony-Stimulating Factor / metabolism. Humans. Killer Cells, Natural / metabolism. Microcirculation. Poly(A)-Binding Proteins. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction. T-Lymphocytes, Cytotoxic / metabolism. Transcription, Genetic

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley-Liss, Inc.
  • (PMID = 12949814.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / DNA Primers; 0 / Membrane Proteins; 0 / Poly(A)-Binding Proteins; 0 / Proteins; 0 / RNA, Neoplasm; 0 / RNA-Binding Proteins; 0 / TIA1 protein, human; 0 / Tumor Necrosis Factor-alpha; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 80168379AG / Doxorubicin
  •  go-up   go-down


19. Komdeur R, Plaat BE, Hoekstra HJ, Molenaar WM, Hollema H, van den Berg E, Mastik MF, van der Graaf WT: Expression of P-glycoprotein, multidrug resistance-associated protein 1, and lung resistance-related protein in human soft tissue sarcomas before and after hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan. Cancer; 2001 May 15;91(10):1940-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of P-glycoprotein, multidrug resistance-associated protein 1, and lung resistance-related protein in human soft tissue sarcomas before and after hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan.
  • Tumor necrosis factor (TNF-alpha) is able to modify the expression of these three proteins in different cell types.
  • The effect of TNF-alpha in the clinical situation on patients with soft tissue sarcomas (STS) is indeterminate.
  • Data from the current study suggest that the combination of TNF-alpha and melphalan does not induce MDR positive STS: a result with clinical importance when consecutive, adjuvant, doxorubicin-containing chemotherapy is considered.
  • [MeSH-major] ATP-Binding Cassette Transporters / metabolism. ATP-Binding Cassette, Sub-Family B, Member 1 / metabolism. Antineoplastic Agents, Alkylating / therapeutic use. Hyperthermia, Induced. Melphalan / therapeutic use. Neoplasm Proteins / metabolism. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy. Tumor Necrosis Factor-alpha / therapeutic use. Vault Ribonucleoprotein Particles / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols. Chemotherapy, Cancer, Regional Perfusion / methods. Drug Resistance, Multiple. Female. Humans. Immunoenzyme Techniques. Interferon-gamma / therapeutic use. Male. Middle Aged. Multidrug Resistance-Associated Proteins. Prognosis. Survival Rate

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. MELPHALAN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 American Cancer Society.
  • (PMID = 11346877.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ATP-Binding Cassette Transporters; 0 / ATP-Binding Cassette, Sub-Family B, Member 1; 0 / Antineoplastic Agents, Alkylating; 0 / Multidrug Resistance-Associated Proteins; 0 / Neoplasm Proteins; 0 / Tumor Necrosis Factor-alpha; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein; 82115-62-6 / Interferon-gamma; Q41OR9510P / Melphalan
  •  go-up   go-down


20. Vliegen RF, Beets GL, Lammering G, Dresen RC, Rutten HJ, Kessels AG, Oei TK, de Bruïne AP, van Engelshoven JM, Beets-Tan RG: Mesorectal fascia invasion after neoadjuvant chemotherapy and radiation therapy for locally advanced rectal cancer: accuracy of MR imaging for prediction. Radiology; 2008 Feb;246(2):454-62
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesorectal fascia invasion after neoadjuvant chemotherapy and radiation therapy for locally advanced rectal cancer: accuracy of MR imaging for prediction.
  • PURPOSE: To retrospectively assess sensitivity and specificity of magnetic resonance (MR) imaging after chemotherapy and radiation therapy for predicting tumor invasion of the mesorectal fascia (MRF) in locally advanced primary rectal cancer, by using results of histologic examination and surgery as the reference standard, and to determine morphologic MR imaging criteria for MRF invasion.
  • The following four types of morphologic tissue patterns at MR imaging were associated with whether or not MRF invasion was present at histologic examination: (a) development of fat pad larger than 2 mm (seen in no quadrants with and in four quadrants without invasion), (b) development or persistence of spiculations (seen in no quadrants with and in 22 quadrants without invasion), (c) development of diffuse hypointense "fibrotic" tissue (seen in 21 quadrants with and in 32 quadrants without invasion), and (d) persistence of diffuse iso- or hyperintense tissue (seen in 19 quadrants with and in two quadrants without invasion).
  • CONCLUSION: Postchemoradiation MR imaging findings have moderate accuracy for predicting tumor invasion of the MRF related to the limitation in differentiating between diffuse "fibrotic" tissue with and that without small tumor foci.
  • Specific other types of morphologic patterns at MR imaging can highly predict a tumor-free or invaded MRF.
  • [MeSH-major] Chemotherapy, Adjuvant. Fascia / pathology. Magnetic Resonance Imaging / methods. Radiotherapy. Rectal Neoplasms / diagnosis. Rectal Neoplasms / therapy. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Treatment Outcome

  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2008.
  • (PMID = 18227541.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Ahmed M, Liu Z, Lukyanov AN, Signoretti S, Horkan C, Monsky WL, Torchilin VP, Goldberg SN: Combination radiofrequency ablation with intratumoral liposomal doxorubicin: effect on drug accumulation and coagulation in multiple tissues and tumor types in animals. Radiology; 2005 May;235(2):469-77
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination radiofrequency ablation with intratumoral liposomal doxorubicin: effect on drug accumulation and coagulation in multiple tissues and tumor types in animals.
  • PURPOSE: To determine whether use of radiofrequency (RF) ablation combined with intravenously (IV) administered liposomal doxorubicin, as compared with use of RF ablation or doxorubicin alone, facilitates increased tissue coagulation and interstitial drug accumulation in animal models.
  • Tumors were assigned to three treatment groups: internally cooled RF ablation (12 minutes, 2000-mA pulsed technique) followed by IV liposomal doxorubicin (10 mg per animal) (n = 6), RF ablation alone (n = 6), and liposomal doxorubicin alone (n = 4).
  • In experiment 2, the livers and kidneys of 10 rabbits and the thigh muscles of 10 rats were randomly assigned to one of two treatment groups: conventional RF ablation (90 degrees C +/- 2, 5 minutes) followed by IV liposomal doxorubicin (5 mg per rabbit, 1 mg per rat) or RF ablation alone (n = 5, each).
  • Coagulation diameter and interstitial doxorubicin concentration (tissues were homogenized in acid alcohol, with doxorubicin extracted for 24 hours at 5 degrees C and quantified with fluorimetry) were measured 48 hours after treatment and compared.
  • Greater but nonuniform drug uptake was observed particularly in this red zone (77.0 ng/g +/- 18.2) compared with uptake in the central zone (15.1 ng/g +/- 3.2), peripheral area of untreated tumor (38.9 ng/g +/- 8.0), and tumors treated with liposomal doxorubicin alone (43.9 ng/g +/- 6.7 for all regions) (P < .01 for all individual comparisons).
  • In experiment 2, use of combined therapy led to increased coagulation in all tissues (liver: 17.6 mm +/- 3.1, P = .03; kidney: 11.0 mm +/- 3.1, P = .03; muscle: 13.1 mm +/- 1.3, P < .01) compared with use of RF ablation alone (liver, 13.4 mm +/- 1.5; kidney, 7.9 mm +/- 0.7; muscle, 8.6 mm +/- 0.5).
  • Combined therapy, as compared with liposomal doxorubicin therapy alone, was also associated with increased doxorubicin accumulation in liver, kidney, and muscle (1.56 microg/g +/- 0.34, 4.36 microg/g +/- 1.78, and 3.63 microg/g +/- 1.43, respectively, vs 1.00 microg/g +/- 0.18, 1.23 microg/g +/- 0.32, and 0.87 microg/g +/- 0.53, respectively) (P < or = .01 for all individual comparisons).
  • CONCLUSION: Use of RF ablation combined with liposomal doxorubicin facilitates increased tissue coagulation and interstitial doxorubicin accumulation in multiple tissues and tumor types and may be useful for treatment of large tumors and achieving an ablative margin within the untreated tissue surrounding RF ablation-treated tumors.
  • [MeSH-major] Catheter Ablation. Doxorubicin / administration & dosage. Kidney / drug effects. Kidney / surgery. Liver / drug effects. Liver / surgery. Muscle, Skeletal / drug effects. Muscle, Skeletal / surgery. Neoplasms, Multiple Primary / drug therapy. Neoplasms, Multiple Primary / surgery. Sarcoma, Experimental / drug therapy. Sarcoma, Experimental / surgery. Soft Tissue Neoplasms / drug therapy. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Animals. Chemotherapy, Adjuvant. Combined Modality Therapy. Drug Synergism. Extracellular Fluid / metabolism. Injections, Intralesional. Necrosis. Neoplasm Transplantation. Rabbits. Rats. Rats, Inbred F344. Tissue Distribution

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2005.
  • (PMID = 15858089.001).
  • [ISSN] 0033-8419
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA 87992-01A1
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin
  •  go-up   go-down


22. Bafaloukos D, Papadimitriou C, Linardou H, Aravantinos G, Papakostas P, Skarlos D, Kosmidis P, Fountzilas G, Gogas H, Kalofonos C, Dimopoulos AM: Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group. Br J Cancer; 2004 Nov 1;91(9):1639-44
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group.
  • Patients with soft tissue sarcoma (STS), even after complete local disease control, often relapse locally or with distant metastases.
  • This multicenter phase II study was conducted to evaluate the safety and efficacy of the combination of pegylated liposomal doxorubicin (PLD) and paclitaxel, as first-line treatment in patients with advanced STS.
  • Histological types included mainly leiomyosarcomas (43%), malignant fibrous histiocytomas (14%) and liposarcomas (12%).
  • At median follow-up 41.5 months, median time to progression (TTP) was 5.7 months with median overall survival (OS) 13.2 months.
  • There were no treatment-related deaths.
  • The combination of PLD and paclitaxel is a safe and well-tolerated regimen demonstrating modest efficacy as first-line treatment in patients with advanced STS.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Histiocytoma, Benign Fibrous / drug therapy. Leiomyosarcoma / drug therapy. Liposarcoma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Sarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Disease Progression. Doxorubicin / administration & dosage. Female. Humans. Liposomes. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lymphatic Metastasis / pathology. Male. Middle Aged. Paclitaxel / administration & dosage. Safety. Survival Rate. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1999 Nov 15;86(10):2034-7 [10570428.001]
  • [Cites] Anticancer Res. 2000 Jan-Feb;20(1B):485-91 [10769710.001]
  • [Cites] Invest New Drugs. 2000 Aug;18(3):253-9 [10958594.001]
  • [Cites] Cancer. 2000 Sep 1;89(5):1037-47 [10964334.001]
  • [Cites] Eur J Cancer. 2001 May;37(7):870-7 [11313175.001]
  • [Cites] Ann Oncol. 2001 Sep;12(9):1281-8 [11697841.001]
  • [Cites] Oncology. 2002;62(3):216-22 [12065868.001]
  • [Cites] Oncologist. 2002;7(4):348-59 [12185297.001]
  • [Cites] Ann Oncol. 2002 Nov;13(11):1737-42 [12419745.001]
  • [Cites] Am J Clin Oncol. 2002 Dec;25(6):561-4 [12477998.001]
  • [Cites] Cancer. 1977 May;39(5):1940-8 [858124.001]
  • [Cites] Cancer Treat Rev. 1977 Jun;4(2):67-86 [329988.001]
  • [Cites] J Clin Oncol. 1987 Jun;5(6):833-5 [3295127.001]
  • [Cites] Semin Oncol. 1990 Apr;17(2 Suppl 4):68-73 [2110386.001]
  • [Cites] J Clin Oncol. 1993 Jan;11(1):15-21 [8418226.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1269-75 [8315424.001]
  • [Cites] Ann Oncol. 1994 Jul;5(6):539-42 [7918126.001]
  • [Cites] Acta Oncol. 1994;33(7):779-86 [7993646.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1537-45 [7602342.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1777-85 [7602367.001]
  • [Cites] J Clin Oncol. 1995 Nov;13(11):2688-99 [7595726.001]
  • [Cites] Nature. 1996 Apr 11;380(6574):561-2 [8606781.001]
  • [Cites] Cancer. 1995 Dec 1;76(11):2248-52 [8635028.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2111-7 [9164225.001]
  • [Cites] Lancet. 1997 Dec 6;350(9092):1647-54 [9400508.001]
  • [Cites] Am J Clin Oncol. 1998 Jun;21(3):241-5 [9626789.001]
  • [Cites] Am J Clin Oncol. 1998 Jun;21(3):317-21 [9626808.001]
  • [Cites] Cancer Invest. 1998;16(7):442-6 [9774950.001]
  • [Cites] Ann Oncol. 1998 Aug;9(8):917-9 [9789617.001]
  • [Cites] Ann Oncol. 1999 Feb;10(2):151-4 [10093682.001]
  • [Cites] Curr Opin Oncol. 1999 Jul;11(4):285-95 [10416881.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):150-7 [10458228.001]
  • (PMID = 15494721.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Liposomes; 80168379AG / Doxorubicin; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ PMC2409958
  •  go-up   go-down


23. Goto T, Okuma T, Nakada I, Hozumi T, Kondo T: [Preoperative adjuvant therapy for primary malignant bone tumors]. Gan To Kagaku Ryoho; 2007 Nov;34(11):1750-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Preoperative adjuvant therapy for primary malignant bone tumors].
  • In primary bone sarcomas, the efficacy of chemotherapy varies according to the histological types.
  • However, because these sarcomas are chemosensitive, their prognoses have been improved with adjuvant chemotherapy.
  • Nowadays, in highgrade bone sarcomas, especially in osteosarcoma, Ewing.s sarcoma and malignant fibrous histiocytoma of bone, adjuvant chemotherapy including neoadjuvant or preoperative chemotherapy is usually performed.
  • The purpose of the neoadjuvant chemotherapy is (I) to prevent distant metastases, (II) to reduce the size of the primary tumor and (III) to evaluate the efficacy of the chemotherapeutic agents.
  • Evaluating the efficacy of the chemotherapeutic agents in preoperative chemotherapy facilitates rational selection of postoperative chemotherapeutic agents.
  • Commonly used drugs include adriamycin, ifosfamide, cisplatin, methotrexate and vincristine in osteosarcoma, and vincristine, adriamycin, cyclophosphamide, ifosfamide, actinomycin-D and etoposide in Ewing's sarcoma.
  • In contrast, chondrosarcomas are chemoresistant, and chemotherapy is rarely performed.
  • Low-grade bone sarcomas, e. g., parosteal osteosarcoma, central low-grade osteosarcoma, are well cured only by surgical excision, and adjuvant chemotherapy is not performed for these low-grade sarcomas.
  • To enhance the efficacy of preoperative chemotherapy, various modalities have been used e. g., intraarterial infusion, caffeine-assisted chemotherapy, and local perfusion with hyperthermia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy
  • [MeSH-minor] Cyclophosphamide / administration & dosage. Dactinomycin / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Humans. Ifosfamide / administration & dosage. Neoadjuvant Therapy. Neoplasm Metastasis / prevention & control. Osteosarcoma / drug therapy. Osteosarcoma / surgery. Prognosis. Sarcoma, Ewing / drug therapy. Sarcoma, Ewing / surgery. Soft Tissue Neoplasms / drug therapy. Soft Tissue Neoplasms / surgery. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18030009.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; UM20QQM95Y / Ifosfamide; VAC protocol; VACA protocol; VAIA protocol
  •  go-up   go-down


24. Poprach A, Michalová E, Pavlík T, Lakomy R, Vyskocil J, Nemeccek R, Zaloudík J, Vyzula R, Kocák I, Kocáková I: [Actual state of ex vivo chemoresistance testing of malignant tumors in Masaryk Memorial Cancer Institute Brno]. Klin Onkol; 2008;21(3):116-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chemoresistance assay results may play a role in cancer management decision process.
  • Five groups of different types of cancer in particular clinical stages were defined for chemosensitivity testing with:.
  • (1) metastatic malignant melanoma, (2) soft tissue sarcoma (STS), either primary or recurrent/metastic, (3) primary or metastatic renal cancer, (4) recurrent ovarian cancer and (5) other diagnosis "on clinician's request".
  • Sensitivity to certain chemotherapy agent observed ex vivo does not necessarily mean that the cancer would also be sensitive to the same agent in vivo, however, ex vivo resistance with following in vivo sensitivity of the tumour has not been observed to date.
  • [MeSH-major] Drug Screening Assays, Antitumor
  • [MeSH-minor] Drug Resistance, Neoplasm. Female. Humans. Kidney Neoplasms / drug therapy. Melanoma / drug therapy. Ovarian Neoplasms / drug therapy. Sarcoma / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19097421.001).
  • [ISSN] 0862-495X
  • [Journal-full-title] Klinická onkologie : casopis Ceské a Slovenské onkologické spolecnosti
  • [ISO-abbreviation] Klin Onkol
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


25. Maki RG, Kraft AS, Scheu K, Yamada J, Wadler S, Antonescu CR, Wright JJ, Schwartz GK: A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas. Cancer; 2005 Apr 1;103(7):1431-8
Hazardous Substances Data Bank. BORTEZOMIB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Arm B accrued patients with other types of soft tissue sarcomas.
  • Patients were not allowed to have received previous chemotherapy for metastatic disease.
  • CONCLUSIONS: Bortezomib has minimal activity in soft tissue sarcoma as a single agent.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Bone Neoplasms / drug therapy. Boronic Acids / therapeutic use. Proteasome Inhibitors. Pyrazines / therapeutic use. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Bortezomib. Drug Administration Schedule. Fatigue / chemically induced. Female. Humans. Male. Middle Aged. Neoplasm Metastasis / drug therapy. Neoplasm Recurrence, Local / drug therapy. Nervous System Diseases / chemically induced. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 15739208.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CM / N01-CM17105; United States / NCI NIH HHS / CA / P01-CA47179
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Proteasome Inhibitors; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  •  go-up   go-down


26. Kobayashi T, Hauck ML, Dodge R, Page RL, Price GS, Williams LE, Hardie EM, Mathews KG, Thrall DE: Preoperative radiotherapy for vaccine associated sarcoma in 92 cats. Vet Radiol Ultrasound; 2002 Sep-Oct;43(5):473-9
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Medical records for 92 cats with a vaccine associated sarcoma receiving preoperative irradiation, with or without chemotherapy, between December 1985 and September 1998 were reviewed.
  • The purposes were to quantify response to treatment and to attempt identification of factors associated with favorable response.
  • Variables evaluated for a relationship to outcome included signalment, tumor location, presence of gross vs. microscopic tumor, radiation field size, irradiation technique, type of surgical procedure, completeness of excision, and chemotherapy (none, carboplatin alone, and others).
  • Time to first event was calculated for the first day of treatment until local tumor recurrence or metastasis, or the date of euthanasia or death.
  • Median time to first event for all 92 cats was 584 days.
  • Only completeness of surgical excision was related to the time to first event.
  • Median time to first event in cats having complete surgical excision was 986 days compared to 292 days for cats with incomplete excision (P = 0.004).
  • Cats requiring bone removal to effect tumor removal had earlier failure than cats having other types of surgery.
  • There was not a significant relationship between administration of chemotherapy or chemotherapy type and time to first event although outcome in cats receiving carboplatin was better than all other treatment groups.
  • Preoperative irradiation is an effective treatment for cats with vaccine associated sarcoma, especially if complete excision can be accomplished following irradiation.
  • [MeSH-major] Cat Diseases / radiotherapy. Cat Diseases / surgery. Neoplasm Recurrence, Local / veterinary. Sarcoma / veterinary. Soft Tissue Neoplasms / veterinary. Vaccination / veterinary
  • [MeSH-minor] Animals. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Carboplatin / administration & dosage. Carboplatin / therapeutic use. Cats. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Female. Male. North Carolina. Preoperative Care / veterinary. Records as Topic / veterinary. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Immunization.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12375783.001).
  • [ISSN] 1058-8183
  • [Journal-full-title] Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association
  • [ISO-abbreviation] Vet Radiol Ultrasound
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin
  •  go-up   go-down


27. Aoki J: [Roles of magnetic resonance imaging in management of bone tumors]. Nihon Igaku Hoshasen Gakkai Zasshi; 2000 May;60(6):295-301
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The roles of magnetic resonance imaging (MRI) in the diagnosis and treatment of bone tumors are reviewed.
  • In characterizing the histologic types of bone tumors, MRI is of some advantage.
  • MRI is now indispensable for the preoperative delineation of malignant bone tumors, because of its excellent soft tissue contrast and multiplanar imaging capability.
  • MRI monitoring of malignant bone tumors after chemotherapy or surgery can reveal change in the size of enhanced areas that may reflect viable tumors.
  • Dynamic MRI is helpful to differentiate recurrent tumors from granulation tissue.
  • [MeSH-major] Bone Neoplasms / diagnosis. Magnetic Resonance Imaging
  • [MeSH-minor] Diagnosis, Differential. Humans. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10860379.001).
  • [ISSN] 0048-0428
  • [Journal-full-title] Nihon Igaku Hōshasen Gakkai zasshi. Nippon acta radiologica
  • [ISO-abbreviation] Nihon Igaku Hoshasen Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] JAPAN
  • [Number-of-references] 23
  •  go-up   go-down


28. Cascio MJ, O'Donnell RJ, Horvai AE: Epithelioid sarcoma expresses epidermal growth factor receptor but gene amplification and kinase domain mutations are rare. Mod Pathol; 2010 Apr;23(4):574-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epithelioid sarcoma is a rare, malignant, soft tissue neoplasm that can be classified into proximal, distal and fibroma-like subtypes.
  • Current therapeutic strategies include surgical resection, amputation, radiation or chemotherapy, although the overall prognosis remains poor.
  • The epidermal growth factor receptor (EGFR) is a novel therapeutic target in carcinomas.
  • EGFR expression has been reported in some sarcoma types, but expression, amplification and mutations have not been studied in epithelioid sarcoma.
  • Thus, the benefit of targeted therapy against EGFR in patients with epithelioid sarcoma remains to be determined.
  • [MeSH-major] Receptor, Epidermal Growth Factor / genetics. Sarcoma / genetics. Sarcoma / metabolism. Soft Tissue Neoplasms / genetics. Soft Tissue Neoplasms / metabolism

  • Genetic Alliance. consumer health - Epithelioid Sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20118913.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


29. Sturgis EM, Potter BO: Sarcomas of the head and neck region. Curr Opin Oncol; 2003 May;15(3):239-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE OF REVIEW: This review discusses the classification, etiology, diagnosis, evaluation, treatment, and prognosis of sarcoma of the head and neck region.
  • Pathologic classification is critical to the ultimate treatment and prognosis of sarcoma of the head and neck.
  • Osteosarcoma, rhabdomyosarcoma, malignant fibrous histiocytoma, and angiosarcoma are the most common types of sarcoma to occur in the head and neck region; however, up to 20% of head and neck sarcomas will remain unclassified.
  • Adjuvant chemotherapy is being utilized and/or studied for most high-grade sarcomas and adjuvant radiotherapy is important for disease control in high-grade soft-tissue sarcomas.
  • [MeSH-major] Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / therapy. Sarcoma / pathology. Sarcoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Female. Hemangiosarcoma / mortality. Hemangiosarcoma / pathology. Hemangiosarcoma / therapy. Humans. Male. Middle Aged. Neoplasm Staging. Osteosarcoma / mortality. Osteosarcoma / pathology. Osteosarcoma / therapy. Prognosis. Radiotherapy, Adjuvant. Rhabdomyosarcoma / mortality. Rhabdomyosarcoma / pathology. Rhabdomyosarcoma / therapy. Risk Assessment. Surgical Procedures, Operative / methods. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12778019.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 157
  •  go-up   go-down


30. Kappler M, Bache M, Bartel F, Kotzsch M, Panian M, Würl P, Blümke K, Schmidt H, Meye A, Taubert H: Knockdown of survivin expression by small interfering RNA reduces the clonogenic survival of human sarcoma cell lines independently of p53. Cancer Gene Ther; 2004 Mar;11(3):186-93
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Survivin, a member of the inhibitors-of-apoptosis gene family, is overexpressed in many tumor types.
  • Survivin is a prognostic marker of soft-tissue sarcomas, but the downregulation of survivin expression and the possible dependency of survivin downregulation on p53 in these tumors have not been investigated.
  • Therefore, we applied small interfering RNA (siRNA) to knock down the expression of survivin in five human sarcoma cell lines with wild-type or mutant p53 alleles.
  • Compared with survivin mRNA expression in the nonsense siRNA-treated sarcoma cell lines, expression after treatment with survivin-specific siRNA was reduced by 73-88%; survivin protein expression was reduced by 52-81%.
  • Our findings suggest that survivin-specific siRNA could be a selective treatment to kill sarcoma cells regardless of the presence or absence of wild-type p53 alleles.
  • [MeSH-major] Microtubule-Associated Proteins / antagonists & inhibitors. RNA, Small Interfering / pharmacology. Sarcoma / therapy
  • [MeSH-minor] Apoptosis. Biomarkers, Tumor. Cell Line, Tumor. Cell Survival. G2 Phase / drug effects. Humans. Immunochemistry. Inhibitor of Apoptosis Proteins. Neoplasm Proteins. Polyploidy. Tumor Stem Cell Assay. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14739938.001).
  • [ISSN] 0929-1903
  • [Journal-full-title] Cancer gene therapy
  • [ISO-abbreviation] Cancer Gene Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / RNA, Small Interfering; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


31. Shon ChN, Baev S: [Diagnosis and treatment of primary retroperitoneal extra-organic tumors]. Khirurgiia (Sofiia); 2000;56(3-4):43-50

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment of primary retroperitoneal extra-organic tumors].
  • Most of PRET are malignant, a the most frequent malignant PRET are soft tissue sarcomas.
  • Because of their specific localization PRETs grow silently for a relatively long period and are often considerably large at the time of diagnosis.
  • Computerized tomography and magnetic resonance imaging are the most useful methods in the diagnosis of PRET.
  • Surgery is the only effective treatment of PRET with exclusion of some histologic types as lymphoma and malignant germ cell tumors.
  • For the malignant PRET, especially the retroperitoneal soft tissue sarcomas, no adjuvant therapy has proved to be beneficial on survival.
  • [MeSH-major] Retroperitoneal Neoplasms / diagnosis. Retroperitoneal Neoplasms / surgery
  • [MeSH-minor] Biomarkers, Tumor. Drug Therapy. Humans. Magnetic Resonance Imaging. Neoplasm Recurrence, Local. Prognosis. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11692918.001).
  • [ISSN] 0450-2167
  • [Journal-full-title] Khirurgii︠a︡
  • [ISO-abbreviation] Khirurgiia (Sofiia)
  • [Language] bul
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Bulgaria
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


32. Tsuyuki S, Kawaguchisakita N, Tsubota Y, Ukikusa M, Kohno Y: [More effective positioning of capecitabine for advanced and metastatic breast cancer]. Gan To Kagaku Ryoho; 2010 Apr;37(4):649-53
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We investigated 30 patients with advanced and metastatic breast cancer who underwent capecitabine therapy in our department from July, 2004 to April, 2009.
  • In comparison with after third-line treatment, capecitabine proved more effective as first or second-line treatment.
  • The soft tissue lesions(primary tumor and metastasis of skin and lymph nodes)showed a significantly better response to capecitabine treatment than other metastases such as lung, liver and bone.
  • There was a significant difference in the response rate between soft tissue metastasis (lymph nodes, skin and primary tumor)and other types of metastasis (lung, liver, and bone).
  • Finally, it was suggested that use of capecitabine in upfront line for HER2-negative expressing cases or soft tissue metastatic cases contributed to the prolongation of time to treatment failure(TTF)and overall survival.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Deoxycytidine / analogs & derivatives. Fluorouracil / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Capecitabine. Female. Humans. Middle Aged. Neoplasm Metastasis / drug therapy. Neoplasm Staging. Receptor, ErbB-2 / metabolism. Survival Rate


33. Nascimento AF, Raut CP, Fletcher CD: Primary angiosarcoma of the breast: clinicopathologic analysis of 49 cases, suggesting that grade is not prognostic. Am J Surg Pathol; 2008 Dec;32(12):1896-904
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mammary angiosarcoma is a rare neoplasm, accounting for about 0.05% of all primary malignancies of the breast.
  • Two patients had a history of prior radiation treatment for breast carcinoma.
  • Forty-six patients were treated surgically, 11 underwent chemotherapy, and 12 patients received radiotherapy.
  • Ten patients (24.4%) showed evidence of local recurrence within 11 to 60 months (median 36) after diagnosis.
  • Twenty-four patients (58.5%) thus far have developed metastases, which were most commonly to lung, liver, skin, and bone.
  • Time interval between diagnosis and metastasis ranged from 2 to 144 months (median 34).
  • This tumor seems to have an overall similar clinical course as other types of angiosarcoma arising in skin or soft tissue; it carries a moderate risk of local recurrence, and a high risk of metastasis and death.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18813119.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Al-Khateeb T, Bataineh AB: Rhabdomyosarcoma of the oral and maxillofacial region in Jordanians: a retrospective analysis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2002 May;93(5):580-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The main outcome measures were age, gender, location, stage of disease, histopathologic type, treatment received, follow-up period, and eventual outcome.
  • Six (67%) bony sites and 7 (78%) soft tissue sites were involved.
  • The histopathologic types found were 6 (67%) embryonal, 2 (22%) alveolar, and 1 (11%) undifferentiated.
  • Triple agent chemotherapy was used in the treatment of 8 cases, singly or in combination with surgery or radiotherapy.
  • [MeSH-minor] Adolescent. Age Factors. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Facial Neoplasms / pathology. Female. Follow-Up Studies. Humans. Jordan. Lymphatic Metastasis / pathology. Male. Neoplasm Staging. Retrospective Studies. Rhabdomyosarcoma, Alveolar / epidemiology. Rhabdomyosarcoma, Embryonal / epidemiology. Sex Factors. Skull Neoplasms / pathology. Statistics as Topic. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12075208.001).
  • [ISSN] 1079-2104
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Higa GM, Abraham J: Biological mechanisms of bevacizumab-associated adverse events. Expert Rev Anticancer Ther; 2009 Jul;9(7):999-1007

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The perception that inhibition of cancer-associated angiogenesis would be an effective treatment strategy was based on the fundamental difference in cell cycle activity between neoplastic and normal endothelial cells.
  • Selective targeting of tumor vessels could have additional benefits, such as circumventing development of acquired resistance to these types of agents, overcoming intrinsic tumor resistance, exhibiting broad anti-tumor activity and decreasing normal tissue toxicity.
  • Successful translation of anti-angiogenic therapy into the clinical setting was achieved only 5 years ago with the approval of bevacizumab for metastatic colorectal cancer.
  • Although the benefits demonstrated in clinical trials led to the approval of bevacizumab for treatment of colorectal, lung and breast cancers, and most recently glioblastoma, a number of serious soft-tissue and vascular toxicities have also been observed in patients receiving this anti-angiogenic agent.
  • [MeSH-minor] Animals. Antibodies, Monoclonal, Humanized. Bevacizumab. Clinical Trials as Topic. Drug Delivery Systems. Drug Resistance, Neoplasm. Humans. Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19589038.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab
  • [Number-of-references] 73
  •  go-up   go-down


36. Dickens DS, Cripe TP: Effect of combined cyclooxygenase-2 and matrix metalloproteinase inhibition on human sarcoma xenografts. J Pediatr Hematol Oncol; 2003 Sep;25(9):709-14
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • COX-2 inhibition is efficacious against many cancer types but has not been tested for human sarcomas.
  • Because MMP inhibitor therapy induces COX-2 expression, the authors hypothesized that the combination of COX-2 and MMP inhibitors results in a synergistic antitumor effect.
  • Tumor development and growth were measured following treatment with a COX-2 inhibitor (celecoxib), an MMP inhibitor (doxycycline), or both.
  • RESULTS: When treatment was started prior to tumor cell implantation, doxycycline inhibited osteosarcoma tumor growth alone and in combination with celecoxib (30% and 33% reduction, respectively).
  • Established osteosarcoma and rhabdomyosarcoma tumors were inhibited only by combination therapy (36% and 55%, respectively).
  • A higher proportion of osteosarcoma tumors in the combination therapy group had more than 50% necrosis (3/7) when compared with control tumors (0/8).
  • CONCLUSIONS: The authors' preclinical data suggest that the combination of inexpensive, nontoxic, oral COX-2 and MMP inhibitors may be useful for the treatment of some types of solid tumors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Isoenzymes / antagonists & inhibitors. Matrix Metalloproteinase Inhibitors. Osteosarcoma / drug therapy. Rhabdomyosarcoma, Embryonal / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Animals. Apoptosis / drug effects. Celecoxib. Cyclooxygenase 2. Cyclooxygenase 2 Inhibitors. Cyclooxygenase Inhibitors / administration & dosage. Dinoprostone / biosynthesis. Doxycycline / administration & dosage. Drug Administration Schedule. Humans. Matrix Metalloproteinase 2 / biosynthesis. Membrane Proteins. Mice. Mice, Nude. Neoplasm Proteins / antagonists & inhibitors. Neoplasm Proteins / biosynthesis. Neoplasm Transplantation. Prostaglandin-Endoperoxide Synthases. Protease Inhibitors / administration & dosage. Pyrazoles. Sulfonamides / administration & dosage. Tumor Cells, Cultured / enzymology. Tumor Cells, Cultured / transplantation. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CELECOXIB .
  • Hazardous Substances Data Bank. DOXYCYCLINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12972806.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclooxygenase 2 Inhibitors; 0 / Cyclooxygenase Inhibitors; 0 / Isoenzymes; 0 / Matrix Metalloproteinase Inhibitors; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / Protease Inhibitors; 0 / Pyrazoles; 0 / Sulfonamides; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases; EC 3.4.24.24 / Matrix Metalloproteinase 2; JCX84Q7J1L / Celecoxib; K7Q1JQR04M / Dinoprostone; N12000U13O / Doxycycline
  •  go-up   go-down


37. Inskip PD, Curtis RE: New malignancies following childhood cancer in the United States, 1973-2002. Int J Cancer; 2007 Nov 15;121(10):2233-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objectives of our study were to quantify risks for developing new malignancies among childhood cancer survivors, identify links between particular types of first and subsequent cancer, and evaluate the possible role of treatment.
  • Observed-to-expected ratios (O/E) were calculated, and Poisson regression was used to compare risks among treatment groups.
  • Most common were subsequent primary cancers of the female breast, central nervous system, bone, thyroid gland and soft tissue, as well as cutaneous melanoma and acute non-lymphocytic leukemia (ANLL).
  • Risk of subsequent solid cancers was higher among persons whose initial treatment for childhood cancer included radiotherapy, whereas the excess of subsequent ANLL was strongly related to chemotherapy.
  • The O/E for subsequent ANLL increased with increasing calendar year of initial cancer diagnosis among survivors of cancers other than HL, most likely due to increasing use of leukemogenic drugs for solid cancers and non-Hodgkin lymphoma.
  • Childhood cancer survivors are at markedly increased risk of developing a variety of new cancers relative to the general population, but the magnitude of excess risk and specific types of second cancer vary widely by type of first cancer.
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Infant. Male. Neoplasm Metastasis. Risk Factors. Sex Characteristics. Time Factors. United States / epidemiology

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17557301.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


38. Chu Q, Mita A, Forouzesh B, Tolcher AW, Schwartz G, Nieto A, Soto-Matos A, Alfaro V, Lebedinsky C, Rowinsky EK: Phase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors. Clin Cancer Res; 2010 May 1;16(9):2656-65
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Blood sampling for PK and drug-drug interaction studies was done.
  • RESULTS: Neutropenia, which resulted in treatment delay exceeding 1 week, was the principal dose-limiting toxicity for this paclitaxel-trabectedin regimen and precluded dose escalation above 120 mg/m(2) paclitaxel and 0.650 mg/m(2) trabectedin.
  • At the MTD (120 mg/m(2) paclitaxel and 0.650 mg/m(2) trabectedin), the safety profile was favorable in patients receiving cumulative treatment.
  • Relevant drug-drug PK interactions between paclitaxel and trabectedin were not identified.
  • A patient with soft tissue sarcoma had a complete response and several patients with various refractory solid malignancies showed protracted stable disease as their best response.
  • The manageable toxicities at the MTD, preliminary evidence of antitumor activity, and lack of notable PK drug-drug interactions warrant further disease-directed studies of this regimen in relevant tumor types and settings.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anemia / chemically induced. Area Under Curve. Dioxoles / administration & dosage. Dioxoles / adverse effects. Dioxoles / pharmacokinetics. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug Resistance, Neoplasm. Fatigue / chemically induced. Feasibility Studies. Female. Humans. Infusions, Intravenous. Leukopenia / chemically induced. Male. Metabolic Clearance Rate. Middle Aged. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Paclitaxel / pharmacokinetics. Tetrahydroisoquinolines / administration & dosage. Tetrahydroisoquinolines / adverse effects. Tetrahydroisoquinolines / pharmacokinetics. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 AACR.
  • (PMID = 20406837.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dioxoles; 0 / Tetrahydroisoquinolines; 114899-77-3 / trabectedin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


39. Khalili P, Arakelian A, Chen G, Plunkett ML, Beck I, Parry GC, Doñate F, Shaw DE, Mazar AP, Rabbani SA: A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol Cancer Ther; 2006 Sep;5(9):2271-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Integrins are expressed by numerous tumor types including breast cancer, in which they play a crucial role in tumor growth and metastasis.
  • Tumor volume was determined at weekly intervals and tumor metastasis was evaluated by X-ray, microcomputed tomography, and histology.
  • RESULT: Treatment with ATN-161 caused a significant dose-dependent decrease in tumor volume and either completely blocked or caused a marked decrease in the incidence and number of skeletal as well as soft tissue metastases.
  • This was confirmed histologically as well as radiographically using X-ray and microcomputed tomography.
  • Treatment with ATN-161 resulted in a significant decrease in the expression of phosphorylated mitogen-activated protein kinase, microvessel density, and cell proliferation in tumors grown in vivo.
  • CONCLUSION: These studies show that ATN-161 can block breast cancer growth and metastasis, and provides a rationale for the clinical development of ATN-161 for the treatment of breast cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Bone Neoplasms / prevention & control. Bone Neoplasms / secondary. Breast Neoplasms / drug therapy. Oligopeptides / pharmacology
  • [MeSH-minor] Animals. Cell Growth Processes / drug effects. Cell Line, Tumor. Female. Green Fluorescent Proteins / biosynthesis. Green Fluorescent Proteins / genetics. Humans. Mice. Mice, Inbred BALB C. Mice, Nude. Neoplasm Metastasis. Neovascularization, Pathologic / drug therapy. Radiography / instrumentation. Soft Tissue Neoplasms / prevention & control. Soft Tissue Neoplasms / secondary. Transfection. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16985061.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oligopeptides; 0 / acetyl-prolyl-histidyl-seryl-cysteinyl-asparaginamide; 147336-22-9 / Green Fluorescent Proteins
  •  go-up   go-down


40. Bień E, Godziński J, Balcerska A, Rapała M, Izycka-Swieszewska E, Stachowicz-Stencel T, Sulka W, Kazanowska B, Reich A, Chybicka A, Madziara W, Bohosiewicz J, Perek-Polnik M, Perek D, Mańkowski P, Jankowski A, Nurzyńska-Flak J, Kowalczyk J, Kurylak A, Wysocki M, Rybczyńska A, Wachowiak J, Zalewska-Szewczyk B, Bodalski J, Jaśkiewicz K: [Malignant vascular tumours in children -- report from the Polish Pediatric Rare Tumors Study]. Med Wieku Rozwoj; 2004 Apr-Jun;8(2 Pt 1):145-58
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant vascular tumours represent a rare group of neoplasms, usually treated according to protocols for soft tissue sarcomas.
  • On the basis of the histological type of the neoplasm these patients have been divided into three groups: group I -- 10 patients with angiosarcoma (ASA), group II -- 7 children with haemangioendothelioma (HE) and group III- 15 patients with haemangiopericytoma (HP), of both infantile (7 children) and adult-types (8 patients).
  • Radiotherapy (RTX) was administered in 5 patients, chemotherapy (CHT) in all.
  • Adult-type HP: PRC was performed in 5 patients, resulting in local control in 4.
  • The high rate of metastatic relapses suggests that the currently given systemic therapy is not satisfactory.
  • The only tumour with excellent prognosis was infantile type HP (all patients are alive and free of disease).
  • Adequate treatment for children with angiosarcoma remains still unknown -- 9 of 10 patients died of disease progression.
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant / methods. Child. Child, Preschool. Female. Humans. Male. Poland. Prognosis. Radiotherapy Dosage. Radiotherapy, Adjuvant / methods. Retrospective Studies. Risk Factors. Survival Analysis. Time Factors. Treatment Outcome

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15738588.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Poland
  •  go-up   go-down


41. Ouyang L, Shen LY, Li T, Liu J: Inhibition effect of Oncostatin M on metastatic human lung cancer cells 95-D in vitro and on murine melanoma cells B16BL6 in vivo. Biomed Res; 2006 Aug;27(4):197-202
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It inhibits the growth of many types of tumor cells, but its role in metastasis is unknown.
  • Clone formation assay in soft agar was used to measure the inhibition activity of OSM on the proliferation of high metastatic human lung cancer cells 95-D.
  • Cell attachment assay, cell migration assay and cell invasion assay were used to evaluate inhibition by OSM on 95-D cells of the adhesion ability, the migration ability, and the ability of cells to cross tissue barriers, respectively.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Cytokines / pharmacology. Lung Neoplasms / drug therapy. Melanoma, Experimental / drug therapy
  • [MeSH-minor] Animals. Humans. Mice. Neoplasm Metastasis. Oncostatin M. Recombinant Proteins / pharmacology

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16971773.001).
  • [ISSN] 0388-6107
  • [Journal-full-title] Biomedical research (Tokyo, Japan)
  • [ISO-abbreviation] Biomed. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cytokines; 0 / OSM protein, human; 0 / Osm protein, mouse; 0 / Recombinant Proteins; 106956-32-5 / Oncostatin M
  •  go-up   go-down


42. Shor AC, Keschman EA, Lee FY, Muro-Cacho C, Letson GD, Trent JC, Pledger WJ, Jove R: Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res; 2007 Mar 15;67(6):2800-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sarcomas are rare malignant mesenchymal tumors for which there are limited treatment options.
  • One potential molecular target for sarcoma treatment is the Src tyrosine kinase.
  • Dasatinib (BMS-354825), a small-molecule inhibitor of Src kinase activity, is a promising cancer therapeutic agent with p.o. bioavailability.
  • Based on our previous findings of Src activation in human sarcomas, we evaluated the effects of dasatinib in 12 cultured human sarcoma cell lines derived from bone and soft tissue sarcomas.
  • These results show that dasatinib inhibits migration and invasion of diverse sarcoma cell types and selectively blocks the survival of bone sarcoma cells.
  • Therefore, dasatinib may provide therapeutic benefit by preventing the growth and metastasis of sarcomas in patients.
  • [MeSH-major] Apoptosis / drug effects. Bone Neoplasms / drug therapy. Cell Movement / drug effects. Osteosarcoma / drug therapy. Pyrimidines / pharmacology. Thiazoles / pharmacology. src-Family Kinases / antagonists & inhibitors. src-Family Kinases / metabolism
  • [MeSH-minor] Cell Line, Tumor. Dasatinib. Enzyme Activation. Humans. Neoplasm Invasiveness. Protein Kinase Inhibitors / pharmacology. Rhabdomyosarcoma / drug therapy. Rhabdomyosarcoma / enzymology. Rhabdomyosarcoma / pathology. Sarcoma, Ewing / drug therapy. Sarcoma, Ewing / enzymology. Sarcoma, Ewing / pathology. Signal Transduction / drug effects

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17363602.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA55652; United States / NCI NIH HHS / CA / CA67360; United States / NCI NIH HHS / CA / CA93544
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Thiazoles; EC 2.7.10.2 / src-Family Kinases; RBZ1571X5H / Dasatinib
  •  go-up   go-down






Advertisement